CN113322222A - Production process of genetic engineering bacteria for expressing feline omega interferon - Google Patents
Production process of genetic engineering bacteria for expressing feline omega interferon Download PDFInfo
- Publication number
- CN113322222A CN113322222A CN202110751063.0A CN202110751063A CN113322222A CN 113322222 A CN113322222 A CN 113322222A CN 202110751063 A CN202110751063 A CN 202110751063A CN 113322222 A CN113322222 A CN 113322222A
- Authority
- CN
- China
- Prior art keywords
- interferon
- solution
- protein
- production process
- renaturation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010050904 Interferons Proteins 0.000 title claims abstract description 75
- 102000014150 Interferons Human genes 0.000 title claims abstract description 74
- 229940079322 interferon Drugs 0.000 title claims abstract description 74
- 241000894006 Bacteria Species 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 241000282324 Felis Species 0.000 title claims abstract description 21
- 238000010353 genetic engineering Methods 0.000 title claims abstract description 7
- 241000282326 Felis catus Species 0.000 claims abstract description 31
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 27
- 238000004153 renaturation Methods 0.000 claims abstract description 25
- 230000014509 gene expression Effects 0.000 claims abstract description 19
- 241000588724 Escherichia coli Species 0.000 claims abstract description 15
- 238000000855 fermentation Methods 0.000 claims abstract description 15
- 230000004151 fermentation Effects 0.000 claims abstract description 15
- 230000001954 sterilising effect Effects 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 11
- 238000000746 purification Methods 0.000 claims abstract description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000005406 washing Methods 0.000 claims abstract description 7
- 238000004925 denaturation Methods 0.000 claims abstract description 6
- 230000036425 denaturation Effects 0.000 claims abstract description 6
- 230000006698 induction Effects 0.000 claims abstract description 6
- 238000005119 centrifugation Methods 0.000 claims abstract description 4
- 238000010276 construction Methods 0.000 claims abstract description 4
- 230000008569 process Effects 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 239000000243 solution Substances 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 239000007983 Tris buffer Substances 0.000 claims description 25
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 14
- 241001052560 Thallis Species 0.000 claims description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004202 carbamide Substances 0.000 claims description 14
- 108020004705 Codon Proteins 0.000 claims description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 6
- 239000013613 expression plasmid Substances 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 229930027917 kanamycin Natural products 0.000 claims description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 6
- 229960000318 kanamycin Drugs 0.000 claims description 6
- 229930182823 kanamycin A Natural products 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 230000009465 prokaryotic expression Effects 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 5
- 239000008118 PEG 6000 Substances 0.000 claims description 5
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 5
- 229940124280 l-arginine Drugs 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 4
- 241000672609 Escherichia coli BL21 Species 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 239000002518 antifoaming agent Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000012148 binding buffer Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000001742 protein purification Methods 0.000 claims description 3
- 239000011265 semifinished product Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 239000012137 tryptone Substances 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 239000003398 denaturant Substances 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 238000005273 aeration Methods 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 abstract description 7
- 230000000120 cytopathologic effect Effects 0.000 abstract description 6
- 239000013642 negative control Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000002900 effect on cell Effects 0.000 abstract 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 description 2
- 208000010717 cat disease Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960005389 moroxydine Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a production process of a genetic engineering bacterium for expressing feline omega interferon, which comprises the following steps: the construction of the cat interferon engineering bacteria and the induction expression production process of the recombinant escherichia coli sequentially comprise fermentation, tank fermentation, centrifugation and crushing, inclusion body washing, denaturation, purification, renaturation and filtration sterilization. The process is simple and effective, and the cells of the negative control hole of the prepared genetically engineered bacteria do not produce anyThe obtained interferon has no toxic or side effect on cells; and a warp 104Dilute cat omega interferon inhibits cytopathic effects by 100%, while 105The diluted interferon had 3 wells with cytopathic effect, 106Cytopathic effect of 5 wells of the double-diluted interferon was observed, and the specific activity of cat omega interferon against VSV was found to be 1.42X 107U/mg。
Description
Technical Field
The invention relates to the technical field of pet drugs, in particular to a production process of a genetic engineering bacterium for expressing feline omega interferon.
Background
With the rapid development of the economy and the continuous improvement of the living standard of people in China, the pet industry in China is also developed rapidly. At present, the number of pet dogs and cats in China is about 1 hundred million, the number of the pet dogs and cats still increases sharply, the consumption around the pets also increases sharply, and the pet dogs and cats show a huge market prospect. However, it is also clear that more and more complex canine and feline diseases, particularly various viral diseases, seriously compromise their health and also threaten human health. The 560 th bulletin of the ministry of agriculture abolishes the use of antiviral western medicines including amantadine, rimantadine, acyclovir, moroxydine (moroxydine), ribavirin and the like, so that extensive veterinarians and culturists urgently need a residue-free and safe antiviral medicine, and interferon serving as a safe biological product fills the gap of the market. The biological activity of interferon and its quick-acting and multifunctional characteristics make it have important significance in preventing viral infectious diseases, inhibiting tumor growth, regulating immunity, etc.
The project aims to construct efficient expression engineering bacteria to induce and express the feline interferon, and prepare an effective feline interferon biological agent, and has important guiding significance for preventing and treating feline diseases, especially various viral diseases.
In general, interferon genes of related cells in an animal body are in a static state, can be expressed only under the induction of factors such as viruses and the like, and have extremely small expression amount, so that direct extraction and purification are difficult. Therefore, when applying interferon to prevent and treat viral diseases, research and development of a way for efficiently producing interferon must be considered. The development and development of recombinant interferon by utilizing genetic engineering technology is an efficient and economic way, and the production of interferon with the advantages of low price, broad-spectrum antiviral activity, no toxicity, no residue and the like is an effective way for promoting the clinical popularization and application of interferon in veterinarians.
At present, the soluble expression quantity of the cat omega interferon engineering bacteria is lower than that of an inclusion body, and the cat omega interferon engineering bacteria are easily influenced by environmental factors, so that the protein coagulation phenomenon is caused, and the expanded production difficulty is increased; the invention aims to provide a production and preparation process of a cat omega interferon inclusion body.
Disclosure of Invention
The invention aims to provide a production process of a genetically engineered bacterium for expressing feline omega interferon aiming at the defects and shortcomings of the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that: the production process of the gene engineering bacteria for expressing the feline omega interferon has the innovation points that the production process comprises the following steps: the method comprises the following steps of constructing cat interferon engineering bacteria and a recombinant escherichia coli induced expression production process, wherein the recombinant escherichia coli induced expression production process sequentially comprises fermentation, tank fermentation, centrifugation and crushing, inclusion body washing, denaturation, purification, renaturation and filtration sterilization, and the specific steps are as follows;
s1, construction of cat interferon engineering bacteria: logging in GenBank, searching a gene sequence (the sequence number is NM-001102440.1) for coding mature protein of cat omega interferon by using SignalP 3.0Server software to predict that the gene may contain a signal peptide sequence which is the first 23 amino acids of the amino acid sequence, using targetP 1.1Server software to detect the function of the sequence, finding that the sequence is necessary for a signal peptide for assisting protein secretion but not a protein structure, thus removing the signal peptide sequence, and leaving a gene sequence for coding mature cat omega interferon, wherein the nucleotide length of the gene sequence is 543; comparing the encoding codon of the cat omega interferon with the preferential codon of escherichia coli, modifying the known gene sequence encoding the cat omega interferon according to the degeneracy of the codon on the basis of not changing the composition and arrangement of amino acids, replacing the modified gene sequence with the preferential codon of escherichia coli, then adding NdeI and XhoI enzyme cutting sites to the 5 'and 3' ends of the replaced gene sequence respectively for complete gene synthesis, and connecting the ends into a prokaryotic expression plasmid pET28a to obtain a recombinant prokaryotic expression plasmid pET28 a-FeIFN-omega; transferring the recombinant plasmid into escherichia coli BL21 to construct and screen out the feline interferon engineering bacteria;
s2, recombinant escherichia coli induced expression production process:
2.1, fermentation: inoculating 1mL of glycerin tube with recombinant plasmid into 200mL of LB culture solution (tryptone 10%, yeast extract powder 5%, sodium chloride 10%) containing kanamycin, culturing at 37 ℃ for 12-18 hours at 200r/min, and preparing first-grade seeds; inoculating the first-stage seed solution to 600mL LB culture solution containing kanamycin in an inoculation amount of 4%, inoculating two bottles together, and culturing at 37 ℃ for 4h at a speed of 200r/min to prepare second-stage seeds;
2.2, fermentation in a tank: after a culture medium and a defoaming agent are filled in a fermentation tank, a secondary seed solution is inoculated according to 5% of the volume of the culture medium after sterilization, aerated culture is carried out at 37 ℃, IPTG with the final concentration of 0.3mM is added for induction expression when the culture is carried out until the OD600 value is 4.0-6.0, then culture is continued for 5-6h, the pH is controlled to be about 6.5, the dissolved oxygen is controlled to be above 30%, and when the solution rises rapidly, feeding is carried out;
2.3, centrifuging and crushing: after the culture is finished, centrifugally collecting thalli, weighing wet and heavy thalli, re-suspending the thalli by using a solution I (pH value is 8.0, 10mmol/L Tris & Cl and 1.0mmol/L EDTA) according to a ratio of 1:20(w/v), crushing the thalli for 3-5 times at 800-1000 bar by using a high-pressure homogenizer, and centrifuging the crushed thalli for 30min at 4 ℃ and 8000r/min to obtain a precipitate, namely an inclusion body;
2.4, washing of inclusion bodies: washing the inclusion bodies with solution II (pH 8.0, 10mmol/L Tris & Cl, 1.0mmol/L EDTA, 1% TritonX-100) and solution III (pH 8.0, 10mmol/L Tris & Cl, 1.0mmol/L EDTA, 2.0mol/L urea) respectively, centrifuging at 4 ℃ for 20 minutes at 8000r/min, and collecting the precipitate, namely the preliminarily purified interferon inclusion bodies:
2.5, denaturation: adding a denaturing solution according to a ratio of 1:40(w/v) to fully dissolve the inclusion body, stirring for 48 hours at 2-8 ℃ to completely dissolve the inclusion body, centrifuging for 10 minutes at 8000r/min at 4 ℃ to collect supernatant, and filtering by 0.22 mu m to obtain the denatured solution of the inclusion body;
2.6, purification: the operation was carried out according to the instructions of the protein purification apparatus using chemical SepharoseTMFast Flow affinity chromatography packing is pre-packed into a column, washed by PBS until the base line is stable, and then balanced to the base line stability by a binding buffer solution (pH value is 8.0, 500mmol/L imidazole, 50mmol/L Tris & Cl, 100mmol/L NaCl and 8.0mol/L urea); after balancing, 10mL of denatured solution is taken for sample loading, and then the mixed protein which is not combined with the chromatographic column is washed away by the combined buffer solution; finally using elution buffer (pH 8.0, 500mmol/L imidazole)50mmol/L Tris & Cl, 100mmol/L NaCl and 8.0mol/L urea) to collect target protein;
2.7, renaturation: measuring the protein content of the collected target protein according to the instructions of a Bradford protein quantitative kit; slowly adding a proper amount of denatured protein to the renaturation solution in batches to ensure that the final concentration of the protein in the renaturation solution is 0.1mg/ml, stirring at the temperature of 2-8 ℃, carrying out renaturation for 24-48 hours, and removing small molecular substances by dialysis after renaturation;
2.8, filtration sterilization: filtering and sterilizing by 0.22 mu m to obtain the interferon semi-finished product.
Further, the denaturing solution in the step of denaturing: pH 8.0, 10mmol/L Tris & Cl, 6.0-8.0mol/L guanidine hydrochloride.
Further, the denaturant: pH 8.0, 10mmol/L Tris. Cl, 7.0mol/L guanidine hydrochloride.
Further, the flow rate at the time of loading and elution in the purification of said step was controlled at 0.5 mL/min.
Further, the renaturation liquid in the renaturation of the step: pH 8.0, 10mmol/L Tris, 400-600mmol/L L-Arg, 500mmol/L urea, 1.0mmol/L EDTA, 2mmol/L cystine, 0.4mmol/L cysteine, 10-15% glycerol, 0.1-0.5% PEG 6000.
Further, the renaturation liquid: pH 8.0, 10mmol/L Tris, 400mmol/L L-Arg, 500mmol/L urea, 1.0mmol/L EDTA, 2mmol/L cystine, 0.4mmol/L cysteine, 10% glycerol, 0.1% PEG 6000.
The invention has the beneficial effects that:
the process is simple and effective, the cells of the negative control hole of the prepared genetic engineering bacteria do not produce any pathological changes, and the obtained interferon has no toxic action on the cells; and a warp 104Dilute cat omega interferon inhibits cytopathic effects by 100%, while 105The diluted interferon had 3 wells with cytopathic effect, 106Cytopathic effect of 5 wells of the double-diluted interferon was observed, and the specific activity of cat omega interferon against VSV was found to be 1.42X 107U/mg。
Drawings
FIG. 1 is an SDS-PAGE protein electrophoresis of cell disruption precipitates;
FIG. 2 is a Western Blot image.
In the figure, M: a protein Marker; 1: IPTG induced expression; 2: expression without IPTG induction.
Detailed Description
The invention will be further described with reference to the accompanying drawings.
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in detail with reference to the accompanying drawings and the detailed description. It should be understood that the detailed description and specific examples, while indicating the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.
A production process of a gene engineering bacterium for expressing feline omega interferon comprises the following steps:
1. construction of cat interferon engineering bacteria:
logging in GenBank, searching a gene sequence (the sequence number is NM-001102440.1) for coding mature protein of cat omega interferon by using SignalP 3.0Server software to predict that the gene may contain a signal peptide sequence which is the first 23 amino acids of the amino acid sequence, using targetP 1.1Server software to detect the function of the sequence, finding that the sequence is necessary for a signal peptide for assisting protein secretion but not a protein structure, thus removing the signal peptide sequence, and leaving a gene sequence for coding mature cat omega interferon, wherein the nucleotide length of the gene sequence is 543; comparing the encoding codon of the cat omega interferon with the preference codon of the escherichia coli, modifying the known gene sequence of the cat omega interferon according to the degeneracy of the codon on the basis of not changing the composition and arrangement of amino acids, and replacing the gene sequence with the preference codon of the escherichia coli, aiming at improving the expression level of the gene in the escherichia coli, wherein the optimized gene sequence is as follows:
ATGTGTGCGCTGCCGGGTAGCCACGCGCAGGTTAGCCGTGATAACCTGGTTCTGCTGGGCCAGATGCGTCGTCTGAGCCCGTTCCTGTGCCTGCGTGCGCGTAAAGATTTCCGTTTCCCGCGTGAAATGCTGGAAGGTGGACAGCTGCGTGAAGCGCAGGCGGCGGCGGCGGTTCTGCGTGAACTGCTGCAGCAGACCTTCAACCTGCTGCACACCGAACGTTCTAGCGCAGCGTGGAGCCCGGCGCCGCTGCACGGCCTGCGTAGCGGCCTGCACCGTCAGCTGGAAGCGCTGGATGCGTGCCTGCTGCAGGCGACTGGCGAAGGTGAACGTGCTACCGGCGAAGGTGAACGTGCGCCGGGCATGCACGGTCCGGTTCTGGCGATCAAACGTTACTTCCAGGATATCCGTGTTTACCTGGAAGATGAAGGCTACTCTGATTGCGCGTGGGAAATCGTTCGTCTGGAAATCATGCGTGCGTTAAGCAGCTCCGCCACCCTGCAAGATTCCTTAGCCATCAAAGACGGCGATCTGGGTAGCAGCTAA
then NdeI and XhoI restriction enzyme sites are respectively added at the 5 'end and the 3' end of the replaced gene sequence, the gene sequence is sent to Shanghai bio-engineering company for whole gene synthesis, and the gene sequence is connected into a prokaryotic expression plasmid pET28a to obtain a recombinant prokaryotic expression plasmid pET28 a-FeIFN-omega; transferring the recombinant plasmid into escherichia coli BL21 to construct and screen the feline interferon engineering bacteria.
2. The recombinant escherichia coli induced expression production process comprises the following steps:
2.1 fermentation
Inoculating 1mL of glycerin tube with recombinant plasmid into 200mL of LB culture solution (tryptone 10%, yeast extract powder 5%, sodium chloride 10%) containing kanamycin, culturing at 37 ℃ for 12-18 hours at 200r/min, and preparing first-grade seeds; the primary seed solution was inoculated into 600mL LB medium containing kanamycin at an inoculum size of 4%, two bottles were inoculated together, and cultured at 37 ℃ for 4 hours at 200r/min to prepare secondary seeds.
2.2 fermentation in tank
After a culture medium and a defoaming agent are filled in a fermentation tank, a secondary seed solution is inoculated according to 5% of the volume of the culture medium after sterilization, aerated culture is carried out at 37 ℃, IPTG with the final concentration of 0.3mM is added for induction expression when the culture is carried out until the OD600 value is 4.0-6.0, then culture is continued for 5-6h, the pH is controlled to be about 6.5, the dissolved oxygen is controlled to be above 30%, and when the solution rises rapidly, feeding is carried out.
2.3 centrifugation and disruption
After the culture is finished, the thalli are collected centrifugally, wet and heavy thalli are weighed, the thalli are resuspended by using solution I (pH value is 8.0, 10mmol/L Tris & Cl and 1.0mmol/L EDTA) according to the proportion of 1:20(w/v), a high-pressure homogenizer is used for crushing 3-5 times at 800-1000 bar, the crushed thalli are centrifuged for 30min at 8000r/min at 4 ℃, and the obtained precipitate is the inclusion body.
2.4 Inclusion body washes
The inclusion bodies are respectively washed once by solution II (pH value is 8.0, 10mmol/L Tris & Cl, 1.0mmol/L EDTA, 1 percent TritonX-100) and solution III (pH value is 8.0, 10mmol/L Tris & Cl, 1.0mmol/L EDTA, 2.0mol/L urea), and the inclusion bodies are centrifuged at 4 ℃ at 8000r/min for 20 minutes to collect precipitates, thus obtaining the preliminarily purified interferon inclusion bodies.
2.5 denaturation
Adding a denaturing solution (pH value of 8.0, 10mmol/L Tris & Cl and 7.0mol/L guanidine hydrochloride) according to a ratio of 1:40(w/v) to fully dissolve the inclusion body, stirring for 48 hours at 2-8 ℃ to completely dissolve the inclusion body, centrifuging for 10 minutes at 8000r/min at 4 ℃ to collect supernatant, and filtering by 0.22 mu m to obtain the denatured solution of the inclusion body.
2.6 purification
The operation was carried out according to the instructions of the protein purification apparatus using the chemical Sepharose of GETMFast Flow affinity chromatography packing is pre-packed into a column, washed by PBS until the base line is stable, and then balanced to the base line stability by a binding buffer solution (pH value is 8.0, 500mmol/L imidazole, 50mmol/L Tris & Cl, 100mmol/L NaCl and 8.0mol/L urea); after balancing, 10mL of denatured solution is taken for sample loading, and then the mixed protein which is not combined with the chromatographic column is washed away by the combined buffer solution; finally eluting with elution buffer solution (pH value 8.0, 500mmol/L imidazole, 50mmol/L Tris & Cl, 100mmol/L NaCl, 8.0mol/L urea) to collect target protein; wherein the flow rate during loading and elution is controlled at 0.5 mL/min.
2.7 renaturation
The protein content of the collected target protein is measured according to the instructions of the Bradford protein quantification kit. Adding a proper amount of denatured protein to renaturation solution (pH value 8.0, 10mmol/L Tris, 400mmol/L L-Arg, 500mmol/L urea, 1.0mmol/L EDTA, 2mmol/L cystine, 0.4mmol/L cysteine, 10% glycerol, 0.1% PEG6000) slowly in batches to ensure that the final concentration of the protein in the renaturation solution is 0.1mg/ml, stirring at the temperature of 2-8 ℃ while adding, carrying out renaturation for 24-48 hours, and removing small molecular substances by dialysis after renaturation.
2.8 Filter Sterilization
Filtering and sterilizing by adopting a 0.22 mu m filter to obtain the interferon semi-finished product.
Furthermore, in the test process, the denatured liquid, the binding liquid in the purification process and the eluent are respectively collected, and after 10-fold dilution, SDS-PAGE and Western Blot detection are carried out to investigate the protein expression effect.
The experimental results are as follows: the results of detecting feline interferon expression by SDS-PAGE and Western Blot are shown in FIGS. 1 and 2.
Further, feline omega interferon activity assays
The recombinant cat omega interferon sample prepared after renaturation is subjected to antiviral activity detection, a micro cytopathy inhibition method is adopted for determination, CRFK is inoculated into a 96-well plate, culture solution is discarded after the CRFK grows into a single layer, 10-time serial dilution of recombinant cat omega interferon is added, 6 times of each dilution are repeated, supernatant is discarded after the culture is carried out for 18-24 hours, 10TCID50 Vesicular Stomatitis Virus (VSV) is used for counteracting the toxicity, meanwhile, a negative control (only 10-time dilution of interferon is added, no virus is added), a positive control (only virus is added, no interferon is added), a blank control (no interferon is added, no virus is added), counteracting and the result is determined after the cytopathy appears in the positive control hole at 75 percent.
The experimental results are as follows: (1) the cells in the negative control wells did not produce any lesions, indicating that the interferon obtained in this example itself had no toxic effect on the cells; (2) warp 104Dilute cat omega interferon inhibits cytopathic effects by 100%, while 105The diluted interferon had 3 wells with cytopathic effect, 106Cytopathic effects occurred in 5 wells of the double-diluted interferon, and the results indicated that the specific activity of feline omega interferon against VSV was 1.42X 107U/mg。
The above description is only for the purpose of illustrating the technical solutions of the present invention and not for the purpose of limiting the same, and other modifications or equivalent substitutions made by those skilled in the art to the technical solutions of the present invention should be covered within the scope of the claims of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (6)
1. A production process of a genetic engineering bacterium for expressing feline omega interferon is characterized by comprising the following steps: the method comprises the following steps of constructing cat interferon engineering bacteria and a recombinant escherichia coli induced expression production process, wherein the recombinant escherichia coli induced expression production process sequentially comprises fermentation, tank fermentation, centrifugation and crushing, inclusion body washing, denaturation, purification, renaturation and filtration sterilization, and the specific steps are as follows;
s1, construction of cat interferon engineering bacteria: logging in GenBank, searching a gene sequence (the sequence number is NM-001102440.1) for coding mature protein of cat omega interferon by using SignalP 3.0Server software to predict that the gene may contain a signal peptide sequence which is the first 23 amino acids of the amino acid sequence, using targetP 1.1Server software to detect the function of the sequence, finding that the sequence is necessary for helping the signal peptide secreted by the protein but not for the protein structure, thus removing the signal peptide sequence, and leaving the gene sequence for coding mature cat omega interferon, wherein the length of the nucleotide is 543 bp; comparing the encoding codon of the cat omega interferon with the preferential codon of escherichia coli, modifying the known gene sequence encoding the cat omega interferon according to the degeneracy of the codon on the basis of not changing the composition and arrangement of amino acids, replacing the modified gene sequence with the preferential codon of escherichia coli, then adding NdeI and XhoI enzyme cutting sites to the 5 'and 3' ends of the replaced gene sequence respectively for complete gene synthesis, and connecting the ends into a prokaryotic expression plasmid pET28a to obtain a recombinant prokaryotic expression plasmid pET28 a-FeIFN-omega; transferring the recombinant plasmid into escherichia coli BL21 to construct and screen out the feline interferon engineering bacteria;
s2, recombinant escherichia coli induced expression production process:
2.1, fermentation: inoculating 1mL of glycerin tube with recombinant plasmid into 200mL of LB culture solution (tryptone 10%, yeast extract powder 5%, sodium chloride 10%) containing 50. mu.g/mL kanamycin, culturing at 37 ℃ for 12-18 hours at 200r/min, and preparing first-grade seeds; inoculating the first-stage seed solution to 600mL LB culture solution containing kanamycin in an inoculation amount of 4%, inoculating two bottles together, and culturing at 37 ℃ for 4h at a speed of 200r/min to prepare second-stage seeds;
2.2, fermentation in a tank: filling culture medium and defoaming agent into fermentation tank, sterilizing, inoculating secondary seed solution at 5% of culture medium volume, culturing at 37 deg.C under aeration, and culturing to OD600When the value is 4.0-6.0, adding IPTG with final concentration of 0.3mM for induction expression, then continuing culturing for 5-6h, controlling pH at about 6.5 and dissolved oxygen at above 30%, and feeding when the solution rises rapidly;
2.3, centrifuging and crushing: after the culture is finished, centrifugally collecting thalli, weighing wet and heavy thalli, re-suspending the thalli by using a solution I (pH value is 8.0, 10mmol/L Tris & Cl and 1.0mmol/L EDTA) according to a ratio of 1:20(w/v), crushing the thalli for 3-5 times at 800-1000 bar by using a high-pressure homogenizer, and centrifuging the crushed thalli for 30min at 4 ℃ and 8000r/min to obtain a precipitate, namely an inclusion body;
2.4, washing of inclusion bodies: washing the inclusion bodies with solution II (pH 8.0, 10mmol/L Tris & Cl, 1.0mmol/L EDTA, 1% TritonX-100) and solution III (pH 8.0, 10mmol/L Tris & Cl, 1.0mmol/L EDTA, 2.0mol/L urea) respectively, centrifuging at 4 ℃ for 20 minutes at 8000r/min, and collecting the precipitate, namely the preliminarily purified interferon inclusion bodies:
2.5, denaturation: adding a denaturing solution according to a ratio of 1:40(w/v) to fully dissolve the inclusion body, stirring for 48 hours at 2-8 ℃ to completely dissolve the inclusion body, centrifuging for 10 minutes at 8000r/min at 4 ℃ to collect supernatant, and filtering by 0.22 mu m to obtain the denatured solution of the inclusion body;
2.6, purification: the operation was carried out according to the instructions of the protein purification apparatus using chemical SepharoseTMA Fast Flow affinity chromatography filler prepacked column is washed by PBS until the base line is stable, and then is balanced to the base line stability by a binding buffer solution (pH value is 8.0, 500mmol/L imidazole, 50mmol/L Tris & Cl, 100mmol/L NaCl and 8.0mol/L urea); after balancing, 10mL of denatured solution is taken for sample loading, and then the mixed protein which is not combined with the chromatographic column is washed away by the combined buffer solution; finally eluting with elution buffer solution (pH value 8.0, 500mmol/L imidazole, 50mmol/L Tris & Cl, 100mmol/L NaCl, 8.0mol/L urea) to collect target protein;
2.7, renaturation: measuring the protein content of the collected target protein according to the instructions of a Bradford protein quantitative kit; slowly adding a proper amount of denatured protein to the renaturation solution in batches to ensure that the final concentration of the protein in the renaturation solution is 0.1mg/ml, stirring at the temperature of 2-8 ℃, carrying out renaturation for 24-48 hours, and removing small molecular substances by dialysis after renaturation;
2.8, filtration sterilization: filtering and sterilizing by adopting a 0.22 mu m filter to obtain the interferon semi-finished product.
2. The process for producing genetically engineered bacteria expressing feline omega interferon according to claim 1, wherein the denaturing solution in the step of denaturing: pH 8.0, 10mmol/L Tris & Cl, 6.0-8.0mol/L guanidine hydrochloride.
3. The production process of the genetically engineered bacterium for expressing feline omega interferon according to claim 2, wherein the denaturant solution comprises: pH 8.0, 10mmol/L Tris. Cl, 7.0mol/L guanidine hydrochloride.
4. The production process of the genetically engineered bacterium for expressing feline omega interferon according to claim 1, wherein the genetically engineered bacterium comprises: the flow rate of the sample loading and elution in the purification of the step is controlled at 0.5 mL/min.
5. The production process of the genetically engineered bacterium expressing feline omega interferon according to claim 1, wherein the renaturation solution in the renaturation step is: pH 8.0, 10mmol/L Tris, 400-600mmol/L L-Arg, 500mmol/L urea, 1.0mmol/L EDTA, 2mmol/L cystine, 0.4mmol/L cysteine, 10-15% glycerol, 0.1-0.5% PEG 6000.
6. The production process of the genetically engineered bacterium expressing feline omega interferon according to claim 5, wherein the renaturation solution: pH 8.0, 10mmol/L Tris, 400mmol/L L-Arg, 500mmol/L urea, 1.0mmol/L EDTA, 2mmol/L cystine, 0.4mmol/L cysteine, 10% glycerol, 0.1% PEG 6000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110751063.0A CN113322222A (en) | 2021-07-02 | 2021-07-02 | Production process of genetic engineering bacteria for expressing feline omega interferon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110751063.0A CN113322222A (en) | 2021-07-02 | 2021-07-02 | Production process of genetic engineering bacteria for expressing feline omega interferon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113322222A true CN113322222A (en) | 2021-08-31 |
Family
ID=77425598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110751063.0A Pending CN113322222A (en) | 2021-07-02 | 2021-07-02 | Production process of genetic engineering bacteria for expressing feline omega interferon |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113322222A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113430220A (en) * | 2021-08-17 | 2021-09-24 | 江苏恒丰强生物技术有限公司 | Synthesis method, construction method and application of genetic engineering bacteria for expressing soluble feline omega interferon |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014933A1 (en) * | 2001-11-22 | 2005-01-20 | Peters Joerg | Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines |
| CN101974555A (en) * | 2010-08-20 | 2011-02-16 | 中国农业大学 | Genetic engineering bacterium for expressing elastase 2B and construction method and application thereof |
| CN106319001A (en) * | 2016-11-28 | 2017-01-11 | 江苏众红生物工程创药研究院有限公司 | Recombinant interferon gamma industrial preparation method and application |
| CN111455006A (en) * | 2020-04-10 | 2020-07-28 | 天津生机集团股份有限公司 | Recombinant chicken interferon α product expressed by escherichia coli and preparation method and application thereof |
| CN112695053A (en) * | 2021-02-05 | 2021-04-23 | 华中农业大学 | Preparation method of recombinant cat interferon |
| CN113430220A (en) * | 2021-08-17 | 2021-09-24 | 江苏恒丰强生物技术有限公司 | Synthesis method, construction method and application of genetic engineering bacteria for expressing soluble feline omega interferon |
-
2021
- 2021-07-02 CN CN202110751063.0A patent/CN113322222A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014933A1 (en) * | 2001-11-22 | 2005-01-20 | Peters Joerg | Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines |
| CN101974555A (en) * | 2010-08-20 | 2011-02-16 | 中国农业大学 | Genetic engineering bacterium for expressing elastase 2B and construction method and application thereof |
| CN106319001A (en) * | 2016-11-28 | 2017-01-11 | 江苏众红生物工程创药研究院有限公司 | Recombinant interferon gamma industrial preparation method and application |
| CN111455006A (en) * | 2020-04-10 | 2020-07-28 | 天津生机集团股份有限公司 | Recombinant chicken interferon α product expressed by escherichia coli and preparation method and application thereof |
| CN112695053A (en) * | 2021-02-05 | 2021-04-23 | 华中农业大学 | Preparation method of recombinant cat interferon |
| CN113430220A (en) * | 2021-08-17 | 2021-09-24 | 江苏恒丰强生物技术有限公司 | Synthesis method, construction method and application of genetic engineering bacteria for expressing soluble feline omega interferon |
Non-Patent Citations (4)
| Title |
|---|
| XIAONA WANG等: "Cloning, prokaryotic soluble expression, and analysis of antiviral activity of two novel feline IFN-ω proteins", 《VIRUSES》, vol. 12, pages 103 * |
| 仇静: "猫α和ω干扰素的原核表达及抗病毒活性测定", 《中国优秀硕士学位论文全文数据库（电子期刊）基础科学辑》, no. 8 * |
| 王继雯;谢宝恩;甄静;周伏忠;陈国参;: "重组Hepcidin融合蛋白的氧化复性及活性鉴定", 生物技术通报, no. 05 * |
| 赵明;蒋贻海;魏波;曲信芹;: "犬干扰素的中试生产工艺及临床前研究", 山东畜牧兽医, no. 12 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113430220A (en) * | 2021-08-17 | 2021-09-24 | 江苏恒丰强生物技术有限公司 | Synthesis method, construction method and application of genetic engineering bacteria for expressing soluble feline omega interferon |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110105436B (en) | ELISA detection kit for porcine circovirus type 3 antibody and preparation method and application thereof | |
| CN104311671A (en) | Cat long-acting fusion interferon as well as preparation method and application thereof | |
| CN113512096A (en) | Weever rhabdovirus recombinant G2 protein and application thereof | |
| CN113322222A (en) | Production process of genetic engineering bacteria for expressing feline omega interferon | |
| CN106011100A (en) | Pfu DNA polymerase and preparation method thereof | |
| CN109055288B (en) | Recombinant bacillus subtilis and application thereof | |
| CN104845996A (en) | Microbiological method for detecting metallic mercury in water body | |
| CN104603280A (en) | Method for the production of polypeptides | |
| CN108840952A (en) | A kind of fusion protein and preparation method thereof being made of Chicken Albumin, chicken interferon gamma and chicken interferon α | |
| CN107200776A (en) | Echinococcus granulosus antigen cC1 recombinant protein and its solubility expression method and purification process | |
| CN106754981A (en) | A kind of method that utilization E. coli system prepares Goose Parvovirus sample particle | |
| CN103613668B (en) | Long-acting fusion interferon for dogs and cats, as well as preparation method and application thereof | |
| CN117843771B (en) | Preparation and application of high-affinity anti-chicken infectious bursal disease virus scFv antibody | |
| CN106243205A (en) | The albumen of a kind of clavacin of degrading and encoding gene thereof and application | |
| CN103146631B (en) | Genetically engineered bacterium for expressing solubility pig gamma-interferonPoIFN-gamma and construction method and application of genetically engineered bacterium | |
| CN102898512B (en) | Recombinant plectasin as well as preparation method and application of recombinant plectasin | |
| CN111218452B (en) | Recombinant human TSG-6 gene, recombinant human TSG-6 protein standard, and preparation methods and applications thereof | |
| CN115181166A (en) | Soluble expression method of O-type foot-and-mouth disease virus VP1 protein | |
| CN101724641A (en) | Method for preparing human serum amyloid A1 and expression vector and genetic engineering bacteria thereof | |
| CN108840934B (en) | Recombinant sheep long-acting interferon tau, fusion protein for preparing long-acting interferon tau and preparation method of fusion protein | |
| CN113430220A (en) | Synthesis method, construction method and application of genetic engineering bacteria for expressing soluble feline omega interferon | |
| CN103509100A (en) | Interleukin-1acceptor antagonist mutant | |
| CN103880962B (en) | Fusion rotein and encoding gene thereof and preparation method and a kind of pharmaceutical composition and preparation method thereof | |
| CN101921799A (en) | Preparation method of horse serum amyloid protein A1 and expression vector and genetic engineering bacteria thereof | |
| CN104561021A (en) | Method for modifying chicken interleukin 2 expressing gene and gene modified by virtue of method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210831 |